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ABSTRACT
FUNCTIONALIZING NANOPARTICLES WITH CAFA PROTEIN
TO TARGET BAR PEPTIDE FOR ORAL DELIVERY
APPLICATIONS
May 1, 2020
Background: Porphyromonas gingivalis adherence to Streptococcus gordonii
may be important for P. gingivalis colonization in the oral cavity. Nanoparticles
encapsulating synthetic peptide BAR (BAR-NPs) inhibit P. gingivalis adherence
more potently than free BAR. However, BAR-NPs would exhibit low retention
in an open flow environment.
Hypothesis: Targeting BAR-NPs to the streptococcal surface using CafA protein
will enhance their efficacy.
Methods: CafA-modified NPs encapsulating BAR were synthesized using double
emulsion approach. Surface binding and retention, and release kinetics of BAR
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from CafA-modified NPs was assessed. Functional inhibition assays were
performed using dual a species biofilm.
Results: CafA-modified NPs demonstrated specificity of adhesion, remained
bound to S. gordonii surfaces and released inhibitory concentrations of BAR for
over 8hr. CafA-modified NPs inhibited P. gingivalis adherence to S. gordonii
potently for over 8hr.
Conclusions: CafA-modified NPs represent a delivery vehicle that targets BAR
to preferred niches of P. gingivalis in the oral cavity.
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CHAPTER 1
INTRODUCTION

Periodontitis is the chronic inflammation of tooth-supporting structures, which begins as
gingivitis and progressively leads to the destruction of periodontal ligament and alveolar bone.
From 2009 to 2012, 46% of adults (age > 30 years) in the United States, were diagnosed with
periodontal diseases. Of these, 8.9% had advanced periodontitis. Domestically, over 14 billion
dollars are spent annually towards the prevention and treatment of periodontal diseases [1].
Periodontal disease is the major cause of tooth loss after the age of 30 and has been
associated with systemic diseases, such as cardiovascular diseases, type 2 diabetes mellitus,
low birth weights, premature labor and osteoporosis [2]. Periodontitis is caused by the
interplay of host susceptibility and changes in the normal microbiota of dental plaque [3].
Role of biofilm in periodontal disease
Periodontal disease is a biofilm-mediated infection. Biofilms consist of a consortium of
organisms that are embedded in a matrix containing extracellular polymeric substances
(EPS). As the bacterial colonies in the biofilm grow, the biofilm develops “emergent properties”
which differ from those of organisms in the planktonic phase [4]. These properties protect the
biofilm and render them resilient to minor environmental alterations. However, environmental
alterations beyond a threshold could prompt competitive overgrowth of certain
microorganisms, leading to dysbiosis and disease [5]. Gaining a thorough understanding of
the mechanism of biofilm formation, its properties, and disease etiology will aid in developing
effective therapeutics for periodontal diseases.
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Formation of dental plaque
Dental plaque is a highly complex biofilm consisting of a diverse bacterial community and their
products [6]. It forms via a series of specific, sequential molecular interactions between
bacteria and host surfaces that ultimately result in the development of a structurally and
functionally organized heterogenous microbial community [7].
Stages of plaque formation:
(i) Initial Adhesion
The formation of dental plaque begins with the developpment of acquired pellicle on the tooth
enamel. The acquired pellicle is a thin coating formed by the adsorption of proteins and other
macromolecules from the saliva and gingival crevicular fluid on the tooth surface. It is
comprised of proline-rich proteins (PRPs), albumin, sialic acid, alpha amylase, and
glycoproteins, and provides substrates for attachment to early colonizing bacteria [8].
Streptococci constitute 80% of these primary colonizers [9, 10] and bind to components of the
salivary pellicle via adhesins, e.g., antigen I/II protein family, amylase-binding adhesin (AbpA),
and serine-rich repeat glycoproteins (Has, GspB) [8, 11, 12]. Actinomyces oris is another
primary colonizer and its adherence to the PRPs and statherin of the salivary pellicle is
mediated via type 1 fimbriae [13]. Initial adherence of the bacteria to the tooth surface is a
crucial event in plaque development which prevents the organisms from being washed away
by mechanical shearing forces of salivary fluid flow and tongue movement [14].

(ii) Bacterial Coaggregation and Biofilm Maturation
After initial adherence, the plaque evolves to contain additional species of bacteria, primarily
consisting of gram-negative rods. Biofilm formation and growth occurs by the adherence of
secondary colonizers to already attached bacterial cells and their metabolic products [14, 15].
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Specific interspecies bacterial adhesion is termed coaggregation and leads to an increase in
the biovolume and complexity of the biofilm [16]. Coaggregation can occur via direct cell-cell
interactions mediated by reciprocal adhesin-receptor binding or via multivalent molecules
such as mucin and glucans [14]. Bacterial coaggregation promotes microbial interactions by
co-locating physiologically relevant organisms in the same milieu, thereby facilitating
development of complex nutritional co-operation, gene transfer and cell-cell signalling [5]. In
microbial communities, nutritional interdependence develops amongst the residing
organisms, where the product of metabolism of one bacterial species becomes the food
source for another, resulting in the development of food webs [4]. Furthermore, metabolic
pathways drive the order of colonization, whereby different layers of the biofilm are associated
with a specific metabolic pathway that results in a functionally-structured community [17]. The
close proximity of the cells also facilitates horizontal gene transfer and increases the adaptive
ability of the organisms to changing oral environment [18]. Moreover, cell-cell signalling
enables bacterial cells to sense and adapt to various environmental stimuli and control the
expression of virulence-regulating genes [5].

As the biofilm grows by bacterial coaagregation, the organisms induce the genetic program
to promote biofilm formation which facilitates interbacterial agglutination by the formation of a
slimy matrix. All microorganisms residing within biofilms are embedded in this matrix
containing extracellular polymeric substances (EPS) [19]. The matrix allows the bacteria to
adhere to each other and the colonizing surfaces, protects the bacteria from host defenses,
enhances the mechanical stability of the biofilm, facilitates communication between bacterial
species, and forms chemical/nutrient gradients that create microenvironments within the
biofilm which vary widely in pH, oxygen and nutrient availability [20, 21]. Thus the matrix allows
individual bacterial cells to behave as a cohesive multicellular unit, whose properties and
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characteristics collectively differ from those of free-living bacteria. These “emergent
properties” of the biofilms make them more conducive to survival in harsher environments [4,
21].

(iii) Biofilm Dispersion
Detachment of cells from the mature biofilm occurs by various processes, e.g., mechanical
sloughing, enzymatic degradation of biofilm matrix, and downregulation of genes responsible
for matrix production [15, 22]. The detached cells disperse and can initiate the formation of a
new biofilm under favorable conditions [22] .

These details surrounding the process of biofilm formation can provide insights for developing
novel, effective strategies to prevent their initial formation (prophylactic approach) and disrupt
existing biofilms (therapeutic approach). Treating biofilm-mediated infections poses a special
challenge due to the “emergent properties” of the biofilm and the resulting biofilm-mediated
resistance [22, 23]. The effectiveness of antibiotics in treating biofilm-mediated infections is
limited due to: (i) compromised penetration of antibiotics through the polysaccharide matrix of
the biofilm [24], (ii) increased drug resistance of bacteria in the biofilm versus planktonic state
[23], and (iii) reduced/altered cellular activity of bacteria within the biofilm [25]. Some novel
anti-biofilm strategies to prevent, weaken or disrupt biofilm formation are illustrated in Figure
1B.
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(A)

(B)

Figure 1: (A) Schematic representation of plaque development. (B) Schematic representation
of anti-biofilm strategies (i) coating tooth surfaces with materials to limit initial bacterial
adherence and prevent biofilm formation, (ii) interrupting bacterial communication to inhibit
development of biofilm properties such as expression of virulence factors, And (iii) disrupting
pre-established mature biofilms using “anti-biofilm” peptides and matrix degrading enzymes
leading to biofilm destabilization.
Image adapted from: Reffuveille, F., et al., Staphylococcus aureus Biofilms and their Impact on the
Medical Field. 2017.
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Etiology of periodontal diseases
The oral cavity harbors more than 700 bacterial species, some of which have been implicated
in the initiation and progression of periodontal diseases. In a study done by Socransky et al.,
it was observed that periodontal diseases are caused by a consortium of organisms rather
than individual pathogens. Moreover, the composition of the microbiome at healthy and
diseased periodontal sites varied drastically and certain microbes were repeatedly found
clustered together at diseased and healthy sites. Based on these findings, five microbial
complexes were defined. Of these, the red complex, which appears later in biofilm
development,

and

comprises

three

species, Tannerella

forsythia,

P.

gingivalis and Treponema denticola, has been considered to be the most pathogenic
microbial complex [26-28].

In recent times, metatranscriptome analysis of dental biofilms from sites with active
periodontal disease have found that in addition to periodontal pathogens such as Tannerella
forsythia and P. gingivalis, organisms such as Veillonella parvula, Pseudomonas fluorescens
and various streptococci are highly active in transcribing putative virulence factors [29]. These
findings have provided evidence for the role of the entire community and not just a few
pathogens in causing the disease.

Our current understanding of periodontal disease is based on the Polymicrobial Synergy and
Dysbiosis model, which proposes that periodontitis is caused by the dysbiosis of the host
microbiome, rather than an exogenous pathogen [3]. P. gingivalis has been shown to play a
key role in inducing dysbiosis by modulating the innate host responses and elevating the
virulence of the microbiome by altering gene expression via interspecies signalling [3, 30].
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One of the proposed ways in which P. gingivalis modulates host immunity is by initiating
C5aR1-TLR2 crosstalk to subvert immune response and promote inflammation [31, 32].
P. gingivalis also suppresses the expression of IL-8 and Th1 chemokines which aid in the
recruitment of neutrophils. Transient delays in neutrophil recruitment facilitate initial
colonization and allow an increase in the overall microbial load [33]. Uncontrolled bacterial
growth disrupts tissue homeostasis and triggers a robust inflammatory response causing
tissue breakdown [34]. Under these circumstances, bacterial species that thrive well in an
inflammatory environment may outcompete those that do not, resulting in a shift in the host
microbiome towards a disease-causing microbiota [3]. Subsequent tissue breakdown yields
nutrients (e.g., degraded collagen and heme compounds) which promote the growth of
subgingival proteolytic and asaccharolytic bacteria. The gene expression of the microbial
community is altered such that genes associated with proteolysis and LPS synthesis are
upregulated [35-37], which in turn leads to more inflammation. The dysbiosis-inflammation
interplay generates a vicious cycle that drives periodontitis [35, 38, 39].

In summary, P. gingivalis may exert a community-wide effect in oral biofilms. It modulates the
host immune response to facilitate an overall increase in bacterial load, along with a shift in
microbial composition to a more disruptive microbial community. The altered microbiota
triggers an uncontrolled inflammatory host response leading to periodontal tissue destruction.
P. gingivalis also alters the gene expression of the microbiome [40]. Thus, P. gingivalis plays
a key role in promoting dysbiosis and elevating the virulence of the host microbiome.

7

Treatment of periodontal diseases
The conventional treatment of periodontal diseases involves the mechanical removal of
plaque/calculus by scaling and root planning, along with the use of antibiotics, administered
by systemic or local routes, as adjuncts to prevent its reoccurrence [41-44]. Systemically
delivered antibiotics reach the deep periodontal pockets, which are not amenable to
professional cleaning, via serum, but require patient compliance and must be administered at
a higher dose to be effective [45]. However, chronic, indiscriminate use of antibiotics in the
treatment of periodontal disease may lead to adverse side effects such as toxicity, allergies,
alteration of gut microflora and increased antimicrobial resistance [46]. Moreover, antibiotic
effectiveness in periodontal treatment is limited due to biofilm-mediated resistance and the
prevalence of resistant pathogens. In a recent study, 25.49%, 23.52% and 21.56% of
P. gingivalis isolates from patients with periodontitis were found to be resistant to amoxicillin,
clindamycin and metronidazole, respectively [47].

Organisms such as P. gingivalis can also evade host immune surveillance by residing and
multiplying within gingival epithelial cells and preventing host cell apoptosis posing a special
challenge in the treatment of periodontitis [48, 49]. At disease sites, P. gingivalis have been
found to reside within all the layers of the epithelial tissue and in the connective tissue [50].
Commonly used antibiotics such as metronidazole do not readily cross the plasma membrane
of cells and therefore are inefficient at killing intracellular organisms. In many cases, after the
cessation of antibiotic therapy, these intracellular organisms recolonize periodontal tissue and
cause recalcitrant disease. These findings underscore the importance of developing
innovative, antimicrobial agents for targeting oral pathogens.
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Why target P. gingivalis?
A longitudinal metatranscriptomic analysis of microbiota from stable to disease-progressing
sites showed that only P. gingivalis expressed virulence factors at healthy sites, whereas the
virulence of T. denticola and T. forsythia was upregulated after tissue breakdown [29]. This
suggests that of all the red complex organisms, P. gingivalis likely initiates dysbiosis at healthy
sites and other organisms contribute to the acceleration of disease process after homeostasis
has already been disrupted [30]. Thus, although P. gingivalis is not essential for periodontal
diseases, it is an important risk factor in periodontal diseases [30].

Studies have also shown that antibody levels to P. gingivalis are consistently higher in patients
diagnosed with adult periodontitis [51, 52]. These findings, combined with the role of P.
gingivalis in inducing host dysbiosis and modulating immunity, makes targeting P. gingivalis
an effective strategy for developing novel therapies for the prevention and treatment of
periodontal diseases.

Current novel treatment strategies targeting P. gingivalis
•

Quorum sensing inhibitors (QSI)
Bacteria in biofilms produce signalling molecules called autoinducers (AI) to communicate
with each other. As the density of the bacteria increases, the concentration of AI also
increases. By sensing the concentration of AI in the environment, bacteria gauge their
population density, and when the density of the population reaches a certain threshold, it
triggers gene expression.. This mechanism of intercellular signalling is known as quorum
sensing (QS) (Figure 2).
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Differential gene expression in response to quorum sensing allows bacteria to modulate their
phenotypes and behavioral activities when growing in biofilms. At low densities, the bacteria
behave as solitary organisms; however, at high densities they develop beneficial traits that
facilitate their survival at a community-level. Quorum sensing-dependent activities include
biofilm development, expression of virulence factors and bioluminescence [53]. For P.
gingivalis specifically, the LuxS/AI-2 signalling system is used for quorum sensing and biofilm
development [54, 55]. Therefore, inhibiting this signalling system can potentially weaken
biofim formation and suppress the expression of the quorum controlled virulence genes [56].
QSI such as furanone compound [(5Z)-4-bromo-5-(bromomethylene)-2(5H)-furanone] and Dribose inhibit AI-2 and have been shown to inhibit P. gingivalis biofilm formation in vitro and
mitigate bone loss in a murine model of periodontitis [57].
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Figure 2: Schematic represention of the mechanism of quorum sensing in bacteria.
Image adapted from: Parray, J., et al., Quorum Sensing: Melody Beneath the Ground. 2018. p.
118. Sankar Ganesh, P. and V. Ravishankar Rai, Alternative Strategies to Regulate Quorum
Sensing and Biofilm Formation of Pathogenic Pseudomonas by Quorum Sensing Inhibitors of
Diverse Origins, in Biotechnological Applications of Quorum Sensing Inhibitors, V.C.
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•

Naturally Derived Compounds
Plant and marine based compounds such as essential oils, capsaicin, chitosan (crustaceans),
andOligoG (oligosaccharide from brown algae alginate) that have the potential to inhibit P.
gingivalis biofilm formation are currently being investigated for therapeutic use [58]. Presently,
a thorough understanding of their precise mechanism of action and cytotoxic potential is
lacking, which precludes their use as therapeutic agents [58]. However, some are believed to
induce this effect by reducing P. gingivalis adherence to gingival epithelial cells, interfering
with proteolylic activity of gingipain and inhibiting cytokine secretion. Some naturally derived
compounds and their mechanism of action have been listed in Table 1 [59-61].

Table 1: Mechanism of action of some naturally derived compounds.
Naturally
Mechanism of Action

Derived
Compound
A-type

•

Anti- P. gingivalis biofilm activity

cranberry

•

Anti-inflammatory (Inhibits IL8 & chemokine ligand 5 secretion)

proanthocyanidin •

Lacinartin

Prenylated
flavonoids

Reduces the adherence of P. gingivalis to oral epithelial cells

•

Anti- P. gingivalis biofilm activity

•

Reduces the adherence of P. gingivalis to oral epithelial cells

•

Disrupts pre-formed biofilms

•

Inhibits P. gingivalis biofilm

•

Interferes with Rgp and Kgp gingipain activity
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•

Antimicrobial Peptides (AMPs)
Antimicrobial peptides have been deemed as promising drug candidates since they are
conserved and therefore exhibit broad-spectrum activity. AMPs target negatively-charged
bacterial cell membranes and kill bacteria by membrane disruption or pore formation [62].
Synthetic AMPs can be engineered to be species-specific with the addition of a targeting
moiety [63, 64]. AMPs also have a lower tendency to induce resistance compared to
conventional antibiotics [64]. Some currently studied antimicrobial peptides are discussed
below.

§

Lactoferrin (LF) is an iron binding glycoprotein and plays an important role in innate immunity.
The lipopolysaccharide (LPS) found on the outer membrane of P. gingivalis is a crucial
virulence factor that mediates its biofilm formation. Lactoferrin binds to LPS and inhibits biofilm
formation. Additionally, P. gingivalis has an absolute requirement of iron for its growth and LF,
due to its ability to sequester iron, can inhibit its growth [65].

§

Nal- p-113 is a cationic AMP which exhibits bactericidal activity by perforating the
plasmalemma, resulting in cell death. Moreover, it is resistant to proteolytic degradation. In
vitro studies have shown that it is effective in eradicating P. gingivalis in the planktonic state
and inhibiting subsequent biofilm formation [66].

§

BAR peptide is a synthetic peptide derived from a specific region of the streptococcal SspB
polypeptide (residues 1167 to 1193) and is comprised of the functional motifs VXXLL and
NITVK. BAR peptide blocks the interaction between P. gingivalis and S. gordonii and
therefore limits the colonization of P. gingivalis and has been shown to reduce virulence in
murine model of periodontitis [67].
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•

Small molecules:
Owing to the high cost of peptide synthesis and the susceptibility of peptides to degradation
by proteases [68], small molecules with antimicrobial activity against P. gingivalis are being
researched for therapeutic potential. For example, BAR peptide consists of lysine residues
that are susceptible to Lys-gingipain expressed by P. gingivalis. 1,2,3-Triazole-based
compounds, formed by joining the synthetic mimics of the functional motifs of BAR peptide
(VXXLL and NITVK) by a click-reaction, have been found to be compact, stable and potent
inhibitors of P. gingivalis – S. gordonii biofilm formation [69, 70]. Of these compounds, PCPIII-201 was found to inhibit P. gingivalis biofilm formation even in the presence of
F. nucleatum, to disrupt pre-established three-species biofilms, and to significantly reduce
alveolar bone loss in murine models of periodontitis [71].

Use of nanotechnology in the control of biofilm mediated infection
In recent times, nanoparticles (NPs) have emerged as promising delivery vehicles to combat
biofilm formation due to their unique nanoscale physicochemical properties [72]. Properties
such as NP size, shape and surface charge help to facilitate or hinder penetration into biofilms
via fluid channels. The self-diffusion coefficient of NPs decreases with the square of the NP
radius [73]. For a constant volume, decreasing the size and increasing the aspect ratio
enhances the efficacy of the NP [74]. Furthermore, while anionic and neutral quantum dots
have been shown to have difficulty penetrating biofilms, cationic quantum dots have been
found to widely distribute throughout biofilms. In addition, factors such as hydrophobicity can
impact bacterial internalization or localization at the bacterial surface. As one example,
cationic quantum dots with hydrophobic terminal groups are more readily internalized by the
bacteria relative to hydrophilic quantum dots which remain in the EPS matrix of the biofilm
[75]. Hence, manipulation of physical attributes such as size and shape, combined with
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chemical characteristics of surface charge and hydrophobicity, can enhance NP penetration
and alter their ability to be internalized by bacteria.

Along with improved biofilm penetration and increased cellular uptake, another advantage of
NPs is the reduced likelihood of resistance development since NPs use several mechanisms
simultaneously to combat microbes [76]. For instance, chitosan nanoparticles have a positive
charge and therefore can associate with negatively-charged bacterial cell walls, increase cell
permeability and cause osmotic damage. Additionally, chitosan can bind to DNA in bacterial
cells and inhibit mRNA transcription and protein translation. It may also decrease the activity
of metalloproteins by chelating metals [77]. Therefore, multiple simultaneous genetic
mutationions are required to occur in the same bacterial cell for resistance development. NPs
may also be used to overcome existing bacterial resistance mechanisms such as permeability
regulation, multidrug efflux pumps and target site mutations [78-80]. Figure 3 depicts some
advantages of using nanosized carriers as drug delivery systems over traditional systematic
and local routes. A more in-depth description of delivery vehicle options that can be used in
oral delivery can be found in review papers by Zupancic, S., et al and Goyal, G., et al.
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• Systemic administration, e.g., tablets and capsules
• Advantages: Ease of administration, inexpensive.
• Disadvantages: High therapeutic dose, low concentration at target
sites, distritution throughout the body, side-effects, resistance
development, frequent dosing.

• Local drug delivery systems, e.g., films and fibers
•Advantages: High concentration at target sites, less frequent dosing,
lower dosing requirements, fewer side-effects, bypass first-pass
effects.
•Disadvantages: Limited dose due to smaller area, need for removal
(fibers), burst release (gels).

• Nanocarrier drug delivery systems, e.g., nanoparticles
and nanofibers
•Advantages: Improved drug stability, protection of drug/peptides,
improved retention and bioadhesiveness, targeted delivery, high
intracellular uptake.
•Disadvantages: Unknown safety profile, complex preparation.

Figure 3: Overview of drug delivery systems.
Image adapted from: Zupancic, S., et al., Contribution of Nanotechnology to Improved
Treatment of Periodontal Disease. Curr Pharm Des, 2015. 21(22): p. 3257-71.
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A wide variety of materials have been used to fabricate nanoparticle delivery vehicles for oral
applications, which include metals and metal oxides, such as silver [81]; gold and copper [82,
83]; lipids [84]; and polymers [85]. Metal and metal oxide particles have been used due to
their inherent antimicrobial properties [86]; however, there are several concerns regarding the
toxicity associated with their accumulation at target sites [87]. Biodegradable materials such
are polymers have gained popularity in recent times due to their biocompatibility, reduced
side-effects, diverse features (e.g., hydrophilicity, lipophilicity) and ease of modifying their
physical properties by changing their chemical structure or by using polymer blends to
optimize NP function [88, 89]. Owing to their ability to be internalized, polymeric NPs can be
developed to address special challenges posed by intracellular dwelling organisms such as
P. gingivalis that can cause recalcitrant disease. Polymersomes encapsulating metronidazole
have been shown to penetrate through two-third of the epithelium in 24 hr and reduce
intracellular P. gingivalis levels significantly relative to free drug, due to their ability to be
internalized by the gingival epithelial cells [90]. Polymeric nanoparticle that repond to stimuli
have been developed to provide more control over the release of the active agent and diminish
undesirable side effects. These NPs demonstrate therapeutic selectivity by responding to
stimuli such as shifts in pH, pressure, temperature and oxygen [91]. Horev et al. designed
farnesol loaded pH-responsive polymeric nanoparticles to bind avidly to the pellicle and EPS
of the biofilm, enhancing drug retention at target sites at physiologic pH. The nanoparticles
were tuned to rapidly release the drug when the local pH became acidic, as would be observed
in a cariogenic environment [92].

In addition to the aforementioned features, polymeric nanoparticles offer some special
advantages such as the protection and stabilization of drugs/proteins, high drug loading
capacity, controlled and sustained drug release, modifiable rate of polymer degradation and
drug release. The rate of polmer degradation can be reduced with the use of hydrophobic
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polymers such as polylactic acid (PLA) and polycaprolactone (PCL) which decrease the
diffusion of water, whereas, the use of hydrophilic polymer such as polyglycolic acid (PGA)
demonstrates the opposite effect. Additionally, the size and surface characteristics of
polymeric NPs can also be easily manipulated to promote penetration of NPs, increase
residence time at target sites and enable site-specific targeting [93]. Lately, there has been a
tremendous interest in developing targeted NPs to improve safety, biodistribution and efficacy
of drugs. In vivo, targeting has been shown to increase accumulation and retention of NPs at
target sites free drug [94-97]. Moreover, localized release of encapsulated agent from the
accumulated NPs at the target sites can enhance the potency of the drug relative to free drug
[94-97].

Development of targeted nanoparticles
Two basic strategies of active and passive targeting have been applied to design NPs that
promote site-specific delivery of active agents. Passive targeting relies on the
physicochemical properties of the NPs (i.e., size, surface charge, mucoadhesivity) and
features of the disease causing agent/disease process (negative charge on bacterial surfaces,
leakiness of tumor vasculature) [98]. Passive targeting strategies have involved integrating
carboxymethyl cellulose (CMC) [99], polyacrylic acid (Carbopol) [100], polyethylene glycol
(PEG) [101, 102], polyvinyl alcohol (PVA) [103] or polyvinyl pyrrolidone (PVP) [103, 104] on
the surfaces of NPs, which has been shown to improve NP retention and accumulation at
target sites. The nanoparticles act as drug depots at target sites and release the active agent
at the desired sites in a controlled and sustained manner [105]. Chitosan has been widely
used in oral applications, due to its inherent mucoadhesive properties [106].

In comparison, active targeting relies on a biological interaction between ligands on the NP
surface and target cell receptors. The use of specific targeting ligands has been shown to
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increase NPs binding efficiency by more than two to four-fold at target sites, due to multivalent
interactions [107-109]. Moreover, minimizing non-specific interactions between NPs and nontarget cells helps to reduce indiscriminate distribution of active agents at non-target sites and
promotes localized delivery to target sites, enhancing NP efficacy [110, 111].

Polymeric nanoparticles and treatment of periodontal diseases
Both passively and actively targeted NPs have been developed for use in the treatment of
periodontal disease.
Passively targeted NPs
Chitosan NPs have been extensively used as passively targeted NPs due to their
mucoadhesive properties. NPs formulated using thiolated chitosan (TCS)-poly (methacrylic
acid) (PMAA) (TCS-PMAA) encapsulating metronidazole benzoate (MET) have been shown
to exhibit high mucoadhesiveness due to water uptake from the mucosal tissue by adsorption,
swelling and capillary effect, leading to stronger adhesion. These NPs also demonstrated
sustained release of MET over 24 hr and improved its oral availability at target sites [112]. In
another study, PLGA-lovastatin-chitosan-tetracycline nanoparticles were found to exhibit
potent antibacterial activity against A. actinomycetemcomitans and P. nigrescens in vitro.
They also improved alkaline phosphatase activity leading to a significant increase in new bone
formation in beagle dogs [113].
Actively targeted NPs
Actively targeted NPs involve modifying the surfaces of the NPs with biological ligands that
promote specific interactions between the ligands on the NP surfaces and target cell
receptors. Several biological ligands such as antibodies, aptamers, peptides and small
molecules have been used to modify the surfaces of the NPs to improve their binding
efficiency on target cells [94, 95]. Often, ligands are directed to exploit endogenous differences
between normal and pathological tissues and to direct therapy to classical or diseased target
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site markers. As one example in periodontitis, inflamed gingival epithelial cells express a
higher level of the b1 integrin including a2b1, a3b1, a5b1 and a6b1, relative to normal epithelial
cells. Surface modification of NPs with a peptide, RGD, which binds to the b1 integrin, helps
to facilitate NP adherence and retention at periodontal disease sites for a prolonged duration.
As such, minocycline-loaded poly(ethylene glycol)-poly(lactic acid) (PEG–PLA) NPs
functionalized with RGD peptides demonstrated potent anti-periodontitis activity relative to
non-targeted NPs and free minocycline [114]. Additionally, RGD-modified minocycline NPs
delivered a higher localized concentration of minocycline to the gingiva and retained the
effective concentration for a longer duration, relative to unmodified minocycline NPs [114].
While few studies have employed active targeting approaches for the treatment of periodontal
diseases, previous work in our group sought to utilize the targeting capabilities of BAR peptide
to improve NP targeting, and thereby enhance potency, via surface-modification. In our
previous work, we developed PLGA nanoparticles functionalized with a synthetic peptide
(BAR) (IC50=0.2 µM), and showed that BAR-modified NPs are more efficacious and inhibit
P.gingivalis adherence to S. gordonii more potently relative to free BAR (IC50=1.3 µM) in vitro.
In murine models of periodontitis, BAR-modified NPs reduced alveolar bone loss and
promoted an anti-inflammatory response by decreasing the expression of IL-17, a proinflammatory cytokine [115].

Considerations for developing actively targeted nanoparticles
Although active targeting can enhance NP efficacy by improving binding efficiency to target
cell receptors, increasing NP residence time at target sites and promoting the localized
delivery of active agents, several factors must be considered in the design of optimally
functioning actively-targeted nanocarriers. Generally, increasing the surface ligand density
improves the receptor binding avidity of surface-modified NPs by promoting multivalent
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interactions. However, several studies have found that NPs with an intermediate ligand
density are more efficacious and exhibit higher binding relative to higher ligand density NPs
[116-118]. This may be due to steric hindrance that affects receptor accessibility (Figure 4A);
increased size of NPs following surface modification, which limits NP diffusion to receptors at
target sites; and improper ligand orientation, with high packing density that interferes with
ligand functionality [105, 119]. It has also been found that the addition of surface ligands
improves binding efficiency only if the receptors are spaced closely enough together to allow
for multiple ligands on the same NP to simultaneously bind to several target cell receptors
(Figure 4B) [119]. Furthermore, receptor clustering due to multiple receptor binding on the
target cell could result in cell activation, proliferation and other adverse effects [105].
Moreover, surface modification with target ligands may impede the release of the encapsulant.
Slower release rates may result in lower available concentrations of the active agent at the
target sites and reduced effectiveness of the surface-modified NPs [107]. Therefore, while
designing NPs for optimal function, the addition of ligands to enhance binding efficiency must
be weighed against its impact on key parameters including encapsulation efficiency, release
kinetics of the encapsulant, and intracellular signalling [107].
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Figure 4: Considerations for developing actively targeted nanoparticles. (A) High ligand
density may not always improve NP binding efficiency. One reason may be limited
accessibility to receptors on the target cell. (B) Binding efficiency improves only when multiple
ligands on the same NP bind to multiple receptors on target cell, promoting multivalent
interactions. However, when receptors on target cell are placed further apart and do not allow
for multiple ligands on the same NP to bind to them simultaneously, addition of ligands does
not improve NP binding efficiency. Figure not drawn to scale.
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BAR peptide
Oral biofilm formation occurs via sequential, species-specific bacterial coaggregation.
One of the bacteria involved in this coaggregation is P. gingivalis, a gram-negative,
assacharolytic, obligatory anaerobe that resides mainly in the subgingival sulcus [120].
However, the subgingival colonization of P. gingivalis is likely to occur only after its initial
colonization within the supragingival biofilm. The initial supragingival colonization of P.
gingivalis is mediated through interactions with certain species of oral streptococci and/or
Fusobacterium nucleatum that provide physiologic support to facilitate its survival in the
supragingival environment [121]. After its supragingival colonization, P. gingivalis disperse
and colonize in their preferred niches of the anaerobic subgingival sulcus [120]. Given the
downstream events initiated by P. gingivalis binding, these initial supragingival interspecies
interactions present viable targets for early therapeutic intervention to limit P. gingivalis
colonization.

One of the primary organisms that promotes the supragingival colonization of P. gingivalis is
S. gordonii. Adherence of P. gingivalis to S. gordonii is a multimodal protein-protein interaction
that involves both the short and long fimbriae of P. gingivalis [122]. FimA, the structural subunit
of the major fimbriae, interacts with cell surface glyceraldehyde 3-phosphate dehydrogenase
of S. gordonii [123, 124], while Mfa1, the structural subunit of the minor fimbriae, interacts with
discrete domains of the streptococcal cell surface protein SspB of the antigen I/II family [125].
The Mfa-SspB interaction is the driving force that mediates interbacterial coaggregation and
is essential for the development of P. gingivalis biofilms on a streptococcal substratum. SspB
polypeptide is 1500 residues in length and consists of seven structural domains that are
conserved in all antigen I/II polypeptides. A region encompassing residues 1167 to 1250
promotes the adherence of SspB protein of S. gordonii to P. gingivalis [126]. Although virtually
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all oral streptococci express antigen I/II proteins, P. gingivalis selectively adheres to certain
species such as S. oralis and S. gordonii but not S. mutans and S. intermedius. Further
comparison of the adherence-promoting region of SspB protein of S. gordonii to the
corresponding region of S. mutans antigen I/II showed that a protein determinant comprising
of 1167 to 1193 was adequate to promote P. gingivalis adherence [127]. The recognition of
this discrete structural motif of SspB (SspB Adherence Region), that is not conserved in SspA,
a related antigen I/II protein of S. mutans, accounts for the species specificity of P. gingivalis
adherence. More specifically, Asn 1182, Thr

1184

and Val1185 in SspB are not conserved in the

SpaP sequence of S. mutans [127].

The synthetic analog of SspB adherence region (BAR), comprised of residues 1167 to 1193,
also potently inhibits Mfa-SspB interaction. It consists of two structural motifs, VXXLL and
NITVK (amino acids 1171 to 1180 and 1182 to 1186, respectively in the full-length antigen I/II
protein of S. gordonii) which are essential for the interaction of the peptide with Mfa.
Additonally, a motif EXXP, upstream of VXXLL, also contributes to the interaction. Analogs of
BAR that lack the EXXP motif, exhibit a lower specific activity relative to BAR [67, 128]. In a
study by Daep et al. it was found that P. gingivalis bound efficiently to BAR-like peptides with
amino acid substitutions at both the non-conserved residues 1182 and 1185. Substitution of
positively-charged amino acids at position 1182 and hydrophobic residues at 1185, further
enhanced the activity of the peptide, whereas substitution with acidic residues at position 1182
reduced P. gingivalis adherence and no other amino acids were tolerated at position 1185.
These findings suggest that the (i) properties and characteristics of the amino acids occupying
these positions were more important, not the specific amino acids, and (ii) Mfa-SspB
interaction is driven by both electrostatic and hydrophobic bonding [67]. Substitution of
cysteine residues for Leu1167 and Leu1191, which yielded a cyclic structurally-constrained
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peptide was found to be a more competitive inhibitor of P. gingivalis biofilm formation than
BAR peptide, suggesting that the secondary structure and conformation of the peptide is
crucial to the function of the peptide. Overall these results suggested that peptides or
peptidomimetics with greater specific inhibitory activity than that of BAR can be synthesized.
In vivo studies demonstrated that BAR peptide inhibits P. gingivalis – S. gordonii biofilm
formation potently mitigates the bone loss in murine model of periodontitis [129].
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Figure 5: Schematic representation of P. gingivalis – S. gordonii interaction. P. gingivalis – S.
gordonii adhesion is mediated via the interaction of major (fimA) and minor fimbriae (Mfa1) of
P. gingivalis and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and discrete
domains on SspA/B (Antigen I/II) adhesin of S. gordonii, respectively. The domains of SspA/B
that interact with the minor fimbriae subunit, Mfa1, are highlighted on the right. These domains
reside within the SspA/B adherence region (BAR) and are required to promote P. gingivalis
adherence. P. gingivalis does not adhere to organisms lacking the BAR motif in the antigen
I/II protein.
Image: Wright, C.J., et al., Microbial interactions in building of communities. Mol Oral
Microbiol, 2013. 28(2): p. 83-101.
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P. gingivalis – S. gordonii Interaction (Figure 6A and B)
P. gingivalis – S. gordonii aggregation is mutualistic and tightly regulated. P. gingivalis – S.
gordonii aggregration is regulated by contact-based signalling and through the detection of
diffusible mediators such as para-amino benzoic acid (pABA). These interactions initially
facilitate the formation of heterotypic community and ultimately limit the development of
excessive microcolonies to prevent states of depleted nutrition and exposure to elevated
levels of oxygen [130, 131].

The accumulation of P. gingivalis on a substratum of S. gordonii is facilitated by increased
expression of mfa1 and luxS genes. Increased transcription of mfa1 results in increased
expression of fimbrial protein, which in turn primes the organism for colonization, whereas,
increased luxS transcription results in elevated levels of AI-2, a quorum signalling molecule
that aids in P. gingivalis – S. gordonii community development [125, 132].

In P. gingivalis, the expression of mfa1 is suppressed through a pathway involving Ltp1 (Low
Molecular Weight Tyrosine Phosphatase), which dephosphorylates Ptk1 and indirectly
upregulates the transcription of CdhR (Community Development and Hemin Regulator), a
negative regulator of luxS and Mfa gene [130].

Following contact with S. gordonii, a streptococci derived contact based signal propogating
through Mfa elevates the levels of Ltp1 in P. gingivalis. Increased Ltp1 levels, indirectly results
in increased CdhR levels, which in turn reduces the transcription of luxS and mfa gene and
consequently restrains P. gingivalis accumulation on S. gordonii. Furthermore, AI-2 is a
negative regulator of CdhR. Therefore, reduced levels of luxS/AI-2 further increases cdhR
expression which further constrains community development. Thus, reduction of AI-2 levels
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compensates for the loss of contact based signalling due to the reduction of Mfa fimbrial
expression and continues to restrain community development [130].

CdhR is a positive regulator of hmu operon involved in hemin uptake and dephosphorylation
of gingipain proteases. Increased levels of CdhR increases hmu transcription and in turn
elevates the pathogenic potential of the organism [130].

In summary, the activation of Ltp1-CdhR pathway in P. gingivalis via contact-based signalling
limits P. gingivalis – S. gordonii heterotypic community development by downregulating the
expression of mfa1 and luxS genes and increases the pathogenicity of P. gingivalis by
upregulating the expression of hmu gene .

Chorismate-binding enzyme encoded by cbe gene in S. gordonii produces a metabolite 4amino benzoate/para-amino benzoic acid (pABA) which can be released extracellularly
(Figure 6a). PABA inactivates Ltp1-CdhR pathway in P. gingivalis and upregulates the
expression of Mfa1 fimbrial protein. Consequently, the dephosphorylation and inactivation of
Ptk1 is reduced. Since Ptk1 activity converges on fimA gene, the level of FimA fimbrial protein
is elevated. Therefore, pABA upregulates the expression of both Mfa1 and FimA, priming the
organism for coadhesion with S. gordonii and community development. Concomitantly, pABA
dimishes the pathogenicity of P. gingivalis by reducing the production of extracellular
polysaccharides. However, following the aggregation of P. gingivalis on S. gordonii, the
calming effects of pABA are reduced, most likely due to spatial constraints in the accessibility
of pABA and subsequently, the pathogenicity of the P. gingivalis – S. gordonii community is
increased due to the activation of the Ltp1-CdhR pathway via contact based signalling [131].
P. gingivalis – S. gordonii coadhesion and signalling is crucial for development of a dysbiotic
microbial community. P. gingivalis virulence is increased following coadhesion with
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S. gordonii . Co-infection with both bacterial species causes a greater amount of alveolar bone
loss relative to infection with either species alone [129]. Therefore blocking these early
interactions could potentially limit the colonization of P. gingivalis and reduce the pathogenicity
of the subsequent biofilm.
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a

Figure 6a: Schematic representation of P. gingivalis – S. gordonii signalling mechanism.
(a) Binding of Mfa1-SspB (contact dependent signalling) increases the levels of Ltp1 and
cdhR(indirectly). Higher levels of cdhR decreases the levels of Mfa and luxS which results in
decreased P. gingivalis – S. gordonii aggregation. Reduction in the levels of AI-2 further
increases the levels of cdhR and limits community development.
Image adapted from : Chawla, A., et al., Community signalling between Streptococcus gordonii

and Porphyromonas gingivalis is controlled by the transcriptional regulator CdhR. Mol
Microbiol, 2010. 78(6): p. 1510-22.
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Figure 6b: Schematic representation of P. gingivalis – S. gordonii signalling mechanism.
(b) Binding of Mfa1 –SspB increases Ltp1 activity and reduces the expression of fimbrial
adhesins. Mfa1-SspB binding also decreases the expression of chorismate binding enzyme
(Cbe), resulting in reduced pABA production. Increased Ltp1 activity and reduced Cbe
expression limits bacterial aggregation and enhances the pathogenicity of P. gingivalis.
Image from: Lamont, R.J., H. Koo, and G. Hajishengallis, The oral microbiota: dynamic
communities and host interactions. Nat Rev Microbiol, 2018. 16(12): p. 745-759.
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Our approach
In our previous work, we demonstrated that a synthetic peptide, consisting of residues 1167
to 1193 of the surface protein SspB expressed by S. gordonii, designated BAR (SspB
Adherence Region), blocks the Mfa1-SspB interaction and reduces the virulence of
P. gingivalis in murine models of periodontitis [67, 129]. However, free peptide is only retained
transiently in the oral cavity owing to the constant flow of saliva. Moreover, while BAR potently
inhibited the initial adherence of P. gingivalis to S. gordonii, it was less effective at inhibiting
pre-established P. gingivalis biofilms.

To enhance the efficacy of BAR peptide (IC50=1.3 µM), we developed polymeric poly (lacticco-glycolic acid) (PLGA) nanoparticles (NPs) encapsulating BAR (BAR-NPs). These NPs
inhibited P. gingivalis – S. gordonii biofilm formation more potently relative to free peptide (IC50
= 0.7 µM). BAR-NPs also disrupted pre-established biofilms more potently than free BAR.

We envision our NPs to be ultimately incorporated in oral hygiene products such as oral gels
which are used two to three times daily. Hence, we ideally seek to develop NPs that will be
retained in the oral cavity and release inhibitory concentrations of BAR peptide for a minimum
of 8 to 12 hours. However, BAR-NPs released > 50% of BAR peptide within the first 2 hr of
delivery and would exhibit low retention in an open flow environment such as the oral cavity
[133]. Hence, the BAR-NPs would benefit from a strategy that would improve their retention
in the oral cavity and promote a gradual release of the BAR peptide.

Several approaches have been employed to improve NP retention, including alteration of
properties such as surface charge and hydrophobicity, and functionalizing NPs with nonspecific mucoadhesive or specific targeting ligands that bind to host receptors [134]. As
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previously discussed, the use of specific targeting ligands has been shown to increase NP
binding efficiency at target sites, due to multivalent interactions with host cell receptors [107109]. These ligands seek to minimize non-specific interactions between NPs and non-target
cells reducing indiscriminate distribution of active agents at non-target sites and promoting
localized delivery at target sites, thereby enhancing NP efficacy [110, 111]. Thus, developing
actively targeted NPs, using specific ligands, is a promising strategy to enhance the efficacy
of NPs. For our experiments, we utilized Coaggregation Factor A protein (CafA) as a targeting
ligand to functionalize the BAR-NPs.
Coaggregation Factor A Protein (CafA)
Actinomyces oris expresses two types of heterodimeric fimbriae:
Type 1 – Mediates the binding of the bacteria to the proline rich salivary proteins which coat
the tooth surface.
Type 2 – Mediates the coaggregation of streptococci and actinomyces species [135].
The type 2 fimbriae is composed of a fimbrial shaft made of FimA subunits and tip fimbrillin
consisting of either FimB or CafA protein. During plaque formation, CafA protein binds to the
GalNAcβ1-3Gal motif of the receptor polysaccharides (RPS) found on oral commensal
streptococci such as S. gordonii and S. oralis, facilitating the coaggregation of actinomyces
and streptococci. Since CafA is the key adhesin which mediates actinomyces−streptococci
binding [136], we anticipated that functionalization of NPs with CafA would enable us to
actively target NPs to areas of the oral cavity harboring commensal streptococci, to gradually
release BAR in P. gingivalis preferred niches.
We hypothesized that modifying the surface of BAR-encapsulated NPs with CafA, would
enhance NP efficacy by augmenting their adhesion to commensal streptococci, facilitating
retention for a longer duration, promoting more gradual release of BAR peptide, and resulting
in potent inhibition of P. gingivalis adhesion to S. gordonii in a dual-species biobiofilm.
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Figure 7: Schematic representation of type 2 fimbriae of A. oris. The type 2 fimbriae facilitates
bacterial coaggregation and consists of a shaft comprising of FimA subunit and tip fimbrillin
consisting of either CafA or FimB.
Image adapted from: Reardon-Robinson, M.E., et al., Pilus hijacking by a bacterial
coaggregation factor critical for oral biofilm development. PNAS, 2014. 111(10): p. 3835-40.
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CHAPTER 2
HYPOTHESIS AND SPECIFIC AIMS

Antibiotics are commonly used as adjuncts in the treatment of periodontal diseases to prevent
its reoccurrence [42-44]. However, the effectiveness of antibiotics in the treatment of
periodontal diseases is limited owing to (i) biofilm-mediated resistance and (ii) reduced
susceptibility of resistant pathogens in subgingival microflora [58]. Therefore, there is a
compelling need to develop novel, targeted, treatment strategies beyond antibiotics for the
prevention and treatment of periodontal diseases.

This project builds on previous work which demonstrated that a synthetic peptide (BAR) blocks
the P. gingivalis – S. gordonii interaction and reduces the virulence of P.gingivalis in the
murine model of periodontitis. Furthermore, nanoparticles encapsulating BAR peptide inhibit
the biofilm formation more potently relative to free BAR [133]. However, similar to free peptide,
NP delivery vehicles may exhibit low retention in an open flow environment such as the oral
cavity, necessitating administration of higher, more frequent doses. Furthermore, due to the
time frame of peptide release (over the course of hours) from BAR-NPs, we hypothesized that
BAR-NPs may benefit from a strategy that augments their retention in an open flow
environment. Our vision is to develop delivery vehicles that will ultimately be incorporated into
oral healthcare products such as oral gels which are commonly used twice daily. Therefore,
ideally, we seek to formulate nanoparticles that will be retained in the oral cavity and release
inhibitory concentrations of BAR peptide for a minimum of 8 to 12 hours.
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Our hypothesis is that modifying the surfaces of NPs with specific targeting moieties such as
CafA will (i) augment the retention of the NPs in the oral cavity via multivalent interactions and
increased avidity of contact with targeted receptor polysaccharides and (ii) prolong the release
of BAR peptide from the NPs by facilitating a more gradual release of the encapsulant.

Thus, the efficacy of the BAR- NPs can be further enhanced by modifying the surfaces of the
BAR-NPs with a specific targeting moiety, such as CafA. Surface modification would augment
the adhesion of the NPs to specific receptors on bacterial surfaces, facilitate their
accumulation at target sites and promote a gradual, localized release of the BAR peptide in
P. gingivalis preferred niches.

To accomplish this, we propose three specific aims:
Specific Aims
1.

Synthesize and characterize CafA-modified nanoparticles encapsulating BAR peptide.

2.

Evaluate the functionality of the surface modification and the release kinetics of BAR
peptide from surface-modified NPs.

3.

Determine the efficacy of the CafA-modified NPs using biofilm inhibition assays.
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Figure 8: (A) Schematic representation of nanoparticles and (B) NP targeting
strategy. Surface modification of nanoparticles with CafA protein will aid in
directing NPs to S. gordonii for targeted delivery of BAR peptide.
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CHAPTER 3
MATERIAL AND METHODS

Peptide Synthesis
BAR peptide consists of residues 1167 to 1193 of the SspB surface protein expressed by
S. gordonii. BAR peptide constitutes the following amino acid sequence:
NH2-LEAAPKKVQDLLKKANITVKGAFQLFS-COOH
To visualize and quantify the release of the peptide from CafA-modified NPs,
6-carboxyfluorescien was covalently attached to the ε – amine of the lysine residue highlighted
in red in the peptide sequence above to produce fluorescent BAR (F-BAR). Functional studies
of CafA-modified NPs was carried out using NPs encapsulating unlabeled BAR peptide. Both
labelled and unlabeled BAR peptide were synthesized by Biosynthesis, Inc. (Lewisville, TX)
and were obtained with a greater than 94% purity.
Growth of Bacterial Strains
Porphyromonas gingivalis ATCC 33277 was cultured in Trypticase soy broth media (TSBY
media) (Difco laboratories Inc., Livonia, MI, USA) supplemented with 0.5% (w/v) yeast extract,
1 μg/ml menadione, and 5 μg/ml hemin. The growth medium was reduced for 24hr in an
anaerobic chamber (10% CO2, 10% H2 and 80% N2). Twenty mls of reduced media was
subsequently inoculated with 2 mls of an overnight P. gingivalis culture and incubated under
anaerobic conditions for 48hrs at 37°C. S. gordonii DL-1, S.oralis SO34, S.mutans KPSP2
and A actinomycetemcomitans 652 were cultured aerobically without shaking in brain-heart
infusion (BHI) broth supplemented with 1% yeast extract for 16 hr at 37°C.
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CafA expression and purification
CafA synthesis was done by isolating the genomic DNA of Actinomyces oris (ATCC 43146)
from 10 mL of an overnight culture using the Wizard Genomic DNA purification kit (Promega,
Madison WI) as specified by manufacturer. The cafA gene was amplified by PCR using 200
ng of genomic DNA as the template and 30 pmol each of the following primers: Forward: 5’AAG GAT CCC TGA GGC CGT TCA -3’; Reverse: 5’- CCG GAA TTC TAC GAC TTG CGG
TTG GAG-3’. PCR amplification was conducted by denaturation at 94°C for 2 min, annealing
of primers and template at 63°C for 30 s, strand extension at 72°C for 2 min 45 s for 30 cycles,
followed by a final extension cycle at 72oC for 5 min.
The PCR product was subsequently electrophoresed in 1% agarose at 90 V for 40 min and
the cafA band was excised and purified using the gel purification kit (Qiagen). The purified
cafA DNA (1 µg) and a sample of the pGEX-6p-1 expression vector (0.5 µg) were digested
with BamHI and EcoRI overnight at 37°C. Prior to ligation, 50 µL of the digested vector were
dephosphorylated with 4 µL calf intestinal alkaline phosphatase (NEB) at 37°C for 30 min.
Subsequently, 3 µL of protease K were added and incubated for 30 min at 50°C to terminate
the reaction. The vector and cafA fragments were purified using the DNA clean and
concentrator kit (Zymoresearch) and ligated with T4 ligase. Ligation reactions comprised 3 µL
vector, 5 µL cafA fragment, 1 µL 10x ligase buffer and 1µL T4 ligase.
The ligation mixture was initially transformed into E. coli Top10. Fifty µL of competent E. coli
Top10 were incubated with 5 µL of ligation mixture on ice for 30 min, then the sample was
heat shocked at 42°C for 45 s and placed on ice for 2 min. Two hundred µL of SOC media
were added, the sample was incubated at 37°C for 1 hr and plated on LB agar. After overnight
incubation at 37°C, single colonies were selected and cultured in 5 mL LB broth supplemented
with 100 µg ampicillin. Plasmid purification was carried out using the miniprep kit (Qiagen)
and the cafA insert was excised and confirmed by sequencing.
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For CafA expression, the purified cafA plasmid was transformed into E. coli BL21 using the
transformation protocol described above. After selecting and confirming the appropriate
transformant, 400 mL of LB broth was inoculated with 10 mL of an overnight culture and
incubated to OD600 of 0.5. Protein expression was induced by the addition of 0.5 mM IPTG
and the culture was then incubated at 18°C for 17 hr. After centrifugation at 4,250 x g, the cell
pellet was suspended in 40 mL 50 mM Tris, 100 mM NaCl, 1 mg/mL lysozome,10 µg/mL
Dnase I, protease inhibitor cocktail, 10 mM CHAPS, incubated overnight at 4°C, then for an
additional 2 hr at 25°C. The cell suspension was then sonicated for 2 min on ice.
CafA purification was carried out with the Pierce GST Spin Purification Kit (Thermo Fisher).
Seventeen mL of crude cell lysate were bound to the GST column for 2 hr at room temperature
and the column was then centrifuged to remove unbound protein according to the
specifications of the manufacturer. After washing the column with loading buffer, the GST tag
was cleaved by the addition of 50 µL precision protease (GE Health) and overnight incubation
at 4°C. Released CafA was then collected by centrifugation. The sample was then sequentially
dialyzed against 30 mM, 20 mM, and 10 mM Tris for 2 hr each. CafA purity was determined
by PAGE gels and protein concentration was determined using the BCA assay (Pierce).

Conjugation of CafA protein with Palmitic acid (CafA-Palmitate Synthesis)
CafA-palmitate was synthesized as previously described [137-139]. Briefly, 2 mg of purified
CafA was dissolved in 1.2 mL of 2% (w/v) sodium deoxycholate (NaDC) in phosphate-buffered
saline (137 mM NaCl, 2.7 mM KCl, 1.8 mM KH2PO4, 10 mM Na2HPO4; PBS) and warmed to
37°C. Next, a solution with 14-fold molar excess of the palmitic acid-N-hydroxysuccinimide
ester (NHS- palmitic acid; Sigma-Aldrich, St Louis, MO, USA) was prepared by dissolving
NHS–palmitic acid in 2% (w/v) NaDC at 0.125 mg/mL. The solution was sonicated until well
mixed in an ultrasonic bath and 800 uL of this solution was added dropwise to the reaction
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vial containing CafA and reacted overnight at 37°C. To remove excess fatty acid and
hydrolyzed ester, reactants were dialyzed against 1.2 L of PBS with 0.15% deoxycholate,
using a 3,500 molecular weight cut-off dialysis tube. After overnight dialysis at 37°C, CafApalmitate was stored at 4°C until use.

Synthesis of CafA-modified nanoparticles
Nanoparticles were synthesized using poly(lactic-co-glycolic acid) (PLGA) carboxylterminated polymer (0.55–0.75 dL/g inherent viscosity; LACTEL®). To formulate CafAmodified nanoparticles, a previously described oil-in-water (o/w) single emulsion technique
was used [140, 141]. Briefly, 100 mg PLGA was dissolved in 2 mL dichloromethane (DCM)
by overnight incubation at 25°C. The next day, 2 mL of 5% (w/v) polyvinyl alcohol (PVA) was
added to 2mL CafA-palmitate solution. This solution was vortexed and 2 mL of PLGA/DCM
solution was added to it in a dropwise manner. The resulting solution was ultrasonicated and
excess DCM was evaporated by adding the solution to 50 mL of 0.3% (w/v) PVA and mixing
using a magnetic stir bar for 3 hr. After evaporation, the NP solution was centrifuged at 13,000
rpm (20,442 x g) at 4°C for 10 min. The supernatant was discarded, and the NPs were washed
twice with deionized water (diH2O) followed by centrifugation at 13,000 rpm (20,442 x g) at
4°C for 10 min. After washing, CafA-modified NPs were suspended in 5 mL of diH2O, freeze
dried at -80°C and lyophilized.

Synthesis of CafA-modified NPs encapsulating C6/F-BAR/BAR
For our experiments, three different types of CafA-modified NPs were synthesized. CafAmodified NPs encapsulating the fluorescent dye, Coumarin6 (C6), were synthesized to assess
the binding functionality of CafA surface modification. CafA-modified NPs encapsulating
fluorescent BAR (F-BAR) were synthesized to determine the loading and controlled release
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characteristics of the NPs, and CafA-modified NPs encapsulating unlabeled BAR were
synthesized to determine the efficacy of NP-mediated inhibition of P. gingivalis adherence to
streptococci using a two-species biofilm model.
CafA-modified NPs encapsulating C6 were synthesized using a previously described w/o/w
double emulsion solvent evaporation technique [138, 139]. Briefly, C6 was dissolved overnight
in 200 μl DCM at a concentration of 15 μg/mg PLGA. In parallel, 100 mg of PLGA crystals
were dissolved in 2 ml of DCM by overnight incubation at 25°C. The following day, the C6
DCM solution was first emulsified in the PLGA/DCM solution by vortexing followed by
ultrasonication to achieve a homogenous suspension. Next, the homogenous suspension was
added dropwise to a mixture of 2ml of 5% (w/v) polyvinyl alcohol (PVA) and 2ml CafApalmitate while vortexing followed by ultrasonication. Excess DCM was evaporated and NPs
were collected as described above. CafA-modified NPs encapsulating F-BAR/BAR were
synthesized using a similar approach. All synthetic reactions were protected from exposure
to light. For the synthesis of CafA-modified NPs encapsulating either F-BAR or unlabeled
BAR, the peptide was dissolved in 200 μl Tris EDTA buffer (VWR; 100 mM Tris HCl,10
mM EDTA at a pH of 8.0; T.E buffer) at a concentration of 43 µg /mg PLGA [133].
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(A)

(B)

Figure 9: (A) Schematic representation of synthesis of CafA-modified NPs encapsulating
BAR peptide using double emulsion solvent evaporation technique. (B) Collection of NPs after
solvent evaporation, centrifugation and washing.
Bottom image adapted from McCall, R.L., Sirianni, R.W. PLGA Nanoparticles Formed by Single or
Double-emulsion with Vitamin E-TPGS. J. Vis. Exp. (82), e51015.
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NP Characterization: NP morphology and size
Unhydrated NP morphology, diameter, and size distribution were determined using scanning
electron microscopy (SEM, XL-30 ESEM-FEG SEM, FEI Company, USA). Lyophilized NPs
were mounted on carbon tape and sputter coated with a thin layer of gold/palladium. Average
diameters of 500 particles were determined from SEM images (n=3) using image analysis
software (ImageJ, National Institutes of Health, version 1.5a, ImageJ.nih.gov).

Quantification of Surface Density of CafA
CafA-modified NPs were synthesized using varying input concentrations of CafA protein
(5 to 80 ug/mg polymer). For each input condition, the resulting concentration of CafA
conjugated to the NP surface was measured using the microBCA assay (Pierce). CafAmodified NPs (1 mg) were suspended in 1% dimethyl sulfoxide (DMSO) in PBS. Aliquots (100
uL) of the NP samples were analyzed in triplicate in a microtiter plate and NP-associated
absorbance was measured by spectrophotometry at a wavelength of 562 nm. The
concentration of CafA was determined by comparing absorbance values to a known standard
curve of CafA and subtracting the background absorbance values of unmodified NPs (control
group).

Loading and release kinetics of BAR peptide from unmodified and CafA-modified NPs
Nanoparticles modified with an intermediate density of CafA (20 ug/mg polymer) were
selected for subsequent characterization and functionality studies. To determine BAR peptide
loading, approximately 2 mg CafA-modified NPs encapsulating F-BAR were dissolved in 1 mL
DMSO. Aliquots (100 uL) of the NP samples were analyzed in triplicate in a microtiter plate
and the amount of F-BAR in the dissolved solution was determined by measuring fluorescence
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(488/518 nm excitation/emission) and quantified by comparing these values to a known
standard curve of F-BAR.
To analyze the release kinetics of F-BAR, aliquots of CafA-modified and unmodified NPs
encapsulating F-BAR were incubated in microcentrifuge tubes containing 1 mL PBS (pH 7.4)
at 37ºC with gentle horizontal agitation. At fixed time points (1, 2, 4, 8, and 24 hr) after the
initial suspension, the samples were centrifuged at 18,900 x g and the supernatant was
collected. The pelleted NPs were then suspended in fresh PBS and incubated until the next
time point. The amount of F-BAR in the supernatant was determined by measuring
fluorescence (488/518nm excitation/emission) and quantified by comparing these values to a
known standard curve of F-BAR.

Determination of functionality of surface modification
The functionality of surface modification and preservation of the function of CafA protein
during NP synthesis was analyzed using two approaches.
To determine the duration of retention of CafA-modified C6 NPs on S. gordonii DL-1 cells,
S. gordonii was cultured as previously described and bacterial cells were harvested by
centrifuging 10 mL of culture at 3700 x g for 5 min. The supernatant was discarded and the
pelleted cells were suspended in 1 mL of 1X PBS. The O.D. at 600 nm of the cell suspension
was adjusted to 0.2 and 100 µL of the S. gordonii cell suspension was added to each well of
a 96-well microtiter plate and incubated overnight at 4°C. After removing unbound cells, the
wells were blocked for non-specific binding with 300 µL of 0.3% bovine serum albumin (BSA)
for 1 hr. Thereafter, the microtiter plate was washed three times with 1X PBS containing 0.05%
Tween (PBST). Immobilized S. gordonii cells were then incubated with 100 µL of CafAmodified C6 NPs (0.25 mg/mL), avidin-modified C6 NPs (0.25 mg/mL) or PBST in the absence
of NPs in triplicate for 1 hr on a rocker platform. After washing three times with PBST, the cell-
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associated fluorescence was measured using Synergy HT reader (BioTek, Winooski, VT,
USA) (485/520 nm excitation/emission). After subtracting the control fluorescence (S. gordonii
in PBST), this initial reading (at t = zero) was defined as 100% binding. After obtaining the
initial reading, 100 µL of PBST was added to each well and at fixed time points (1, 2, 4 and 8
hr), the PBST was removed and the cell-associated fluorescence that remained was
measured. Subsequently, an additional aliquot of fresh PBST was added per well and
incubated until the next time point was reached.
For determining the specificity of CafA adhesion, the adherence of CafA-modified C6 NPs to
S. gordonii DL-1, S. oralis SO34, P. gingivalis ATCC 33277, A. actinomycetemcomitans 652
or S. mutans KPSP2 cells was measured. CafA binds to receptor polysaccharides (RPS)
found only on commensal oral streptococci such as S. gordonii and S. oralis. It does not bind
to bacteria that are RPS- negative and therefore, P. gingivalis ATCC 33277, A.
actinomycetemcomitans 652 and S. mutans KPSP2 were selected as negative bacterial
controls. Each of the organisms was cultured and harvested as described previously, and the
final O.D. at 600 nm for each cell suspension was adjusted to 0.2. The bacterial cells were
immobilized on a 96-well microtiter plate as described above and after overnight incubation,
wells were blocked for non-specific binding with 300 µL of 3% bovine serum albumin (BSA)
for 1 hr. The plate was washed three times with PBST and immobilized bacterial cells were
incubated with 100 µL of CafA-modified C6 NPs (0.25 mg/mL) or with PBST in triplicate for 1
hr on a rocker platform. The microtiter plate was again washed three times with PBST and
cell-associated fluorescence was measured (485/520 nm excitation/emission). To determine
the final cell associated fluorescence, the reading obtained from bacteria incubated in PBST
alone (background) was subtracted from that of bacteria incubated with CafA-modified C6
NPs. Data was analyzed using an unpaired t-test.
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Figure 10: Schematic of duration of retention assay. S. gordonii cells were immobilized on a
microtiter plate and incubated with CafA C6-NPs. At fixed time points, the supernatant
containing the unbound NPs was removed and the cell associated fluorescence was
measured. Thereafter, fresh buffer was added to the wells, until the next time point was
reached. Avidin-modified C6 NPs were used as controls. To measure specificity of adhesion,
adherence of CafA-modified NPs to S. mutans KPSP2, S. oralis SO34, P. gingivalis ATCC
33277 or A. actinomycetemcomitans 652 cells was compared to the level of adherence to S.
gordonii DL-1 cells.

47

CafA-modified NP-mediated inhibition of P. gingivalis adherence to streptococci
S. gordonii DL-1 was cultured as previously described and bacterial cells were harvested by
centrifuging 10 mL of culture at 3700 x g for 5 min. The supernatant was discarded, and the
pelleted cells were suspended in 1 mL of 1X PBS in a microcentrifuge tube. The cells were
labelled with 20 µL of 10 mM hexidium iodide (Thermo Fisher Scientific) for 15 min on a rocker
platform at room temperature. The microcentrifuge tube was covered with foil, centrifuged at
3700 x g for 5 min, and the pelleted cells were suspended in 1 mL of 1X PBS. The O.D. at
600 nm was measured as previously described and adjusted to 0.8. One mL of the resulting
cell suspension was added to each well of a 12-well microtiter plate containing a glass
coverslip. The cells were incubated overnight under anaerobic conditions on a rocker platform
and protected from light.
On the following day, the wells were washed to remove unbound S. gordonii cells. The
immobilized S. gordonii cells were incubated with CafA-modified BAR NPs (treatment) or
CafA-modified blank NPs (control) at a concentration of 240 µg/mL for different durations on
a rocker platform. Due to the 50% inhibitory concentration (IC50) of free BAR peptide
equivalent to 1.3 µM or ~4 µg, and NP loading results, we calculated that 240 µg CafAmodified BAR NPs would encapsulate an equivalent amount of BAR. After the first hour of
binding (t = 0) and at each subsequent time point (t = 2, 4, 8, 12 hr) the supernatant containing
the unbound NPs and released BAR was removed and P. gingivalis was added in triplicate to
the control and treatment plates as described below.
P. gingivalis ATCC 33277 was cultured and harvested as previously described. P. gingivalis
was labelled with 15 µL of 5-(6) carboxyfluorescien-succinylester (4 mg/mL) for 30 min,
centrifuged at 3700 x g for 2 min and the pelleted cells were suspended in 1 mL of 1X PBS.
The O.D. at 600 nm was measured and adjusted to 0.4. At each time point, 1 mL of labelled
P. gingivalis cell suspension (O.D. 0.4) was added to the treatment and control plates in
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triplicate. The plates were incubated at 37 °C for 24 hr under anaerobic conditions. The
subsequent day the supernatant was removed, the wells were washed with 1X PBS to remove
the unbound bacterial cells. The adherent cells were fixed with 4% (w/v) paraformaldehyde.
The coverslips were mounted on a glass slide using Prolong gold anti-fade reagent and fixed
with clear nail polish. The prepared slides were stored at 4°C.

Confocal Microscopy and Imaging
The dual-species biofilms were visualized using a LEICA SP8 confocal microscope (Lieca
Microsystems Inc., Buffalo Grove, IL) under 60 X magnification. Three dimensional z-stack
biofilm images were obtained using a z-step size of 0.7 µm. Images were analyzed using
Volocity software (version 6.3; Perkin Elmer, Waltham, MA, USA) to quantify the bacterial
populations by quantifying fluorescence (S. gordonii – red, P. gingivalis – green). Adherence
of P. gingivalis to streptococci was determined by measuring the green to red fluorescence
ratio (GR). Inhibition at each time point was analyzed in triplicate (treatment and control plates)
and three independent frames were obtained for each well. The percentage of P. gingivalis
inhibition was calculated using the formula: (1- GR treatment /GR control) * 100. The mean
and S.D. of inhibition at each time point was calculated and the data was analyzed using a
paired t-test.
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Visualize
biofilms using confocal
microscope

Measure GR ratio using Volocity software
% adherence inhibition P. g. = 1-GR(S)/GR(C)×100

Figure 11: Schematic representation of inhibition assay using dual-species biofilm. The
efficacy of the CafA-modified NPs was evaluated by performing functional inhibition assays
using a two species biofilm model.
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CHAPTER 4
RESULTS

NP Characterization: NP morphology and size
The morphology of CafA-modified BAR NPs, relative to unmodified BAR NPs, is shown in
Figure 12. CafA-modified BAR NPs demonstrated a spherical morphology and were smaller
relative to unmodified BAR NPs. The average unhydrated diameters of CafA-modified BAR
NPs and unmodified BAR NPs measured from SEM images were 89.7 ± 26.3 nm and 165.8
± 33.4 nm, respectively.
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*Figure 12: SEM images of (A) CafA-modified BAR-encapsulated NPs and (B) Unmodified
BAR-encapsulated NPs PLGA NPs. Images are representative of a minimum of 3
independent samples, with n > 500 NPs assessed in total. Scale bar represents 1 µm.
*This data was collected by Mohamed Y. Mahmoudd
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Quantification of ligand surface density

The concentration of CafA conjugated to the surface of the NP was measured using the
microBCA assay. The total protein content ranged from 3 to 36 µg CafA/mg polymer and
varied directly with the input concentration of CafA (5 to 80 µg CafA/mg polymer) used during
synthesis. The conjugation efficiency ranged from 45 to 79%, with higher conjugation
efficiency observed at lower concentrations (Figure 13, Table 2). Although saturation was not
achieved under these conditions, the results suggest that an increased surface density may be
attained with higher CafA input.
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**Figure 13: Quantification of surface density of ligands. The total amount of CafA conjugated
to the NP surface was determined using the microBCA assay. The amount of CafA conjugated
to the NP surface varied directly with the input concentration of CafA during synthesis. Data
represent mean NP associated CafA ± S.D, n = 3.

Table 2: Input and output concentration of CafA

Input
Concentration
(µg CafA/ mg NP)
5

Output
Concentration
(µg CafA/ mg NP)
2.9 ± 0.1

10

7.9 ± 1.9

79

20

14.4 ± 2.6

72

40

25.4 ± 2.2

64

80

36.3 ± 3.5
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**Data collected together with Mohamed Y. Mahmoudd
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Conjugation
Efficiency (%)
58

Loading and release kinetics of BAR peptide from unmodified and CafA-modified NPs
Nanoparticles modified with an intermediate density of CafA (20 ug/mg polymer) were
selected for subsequent characterization and functionality studies, as they represent a
practical minimum modification density that in preliminary studies (and results here) provided
a therapeutically-relevant concentration of BAR release. To determine the loading of BAR
peptide in unmodified and CafA-modified NPs, the amount of F-BAR from dissolved NPs was
determined by measuring fluorescence (488/518 nm excitation/emission) and quantified by
comparing these values to an F-BAR standard curve. Loading experiments showed that
unmodified and CafA-modified NPs encapsulated 16.95 ± 0.8 and 15.73 ± 1.9 µg of BAR per
mg of NP respectively, corresponding to loading efficiencies of 39% and 37% (Table 3),
suggesting that surface modification at this density had minimal effect on BAR loading.
To measure BAR release, sample eluates were taken 1, 2, 4, 8, and 24 hr after incubation in
PBS. The overall release trends showed that CafA-modified NPs demonstrated slower
release of BAR, relative to unmodified NPs; however, inhibitory concentrations of BAR peptide
(2 to 4 µg/mg NP) were released from CafA-modified NPs at each of the measured time points
up to 8 hr. For unmodified NPs, more rapid release profiles were observed, with greater than
50% of BAR peptide released within 1 hr and a plateau in release after. After 2, 4, 8 and 24
hr, less than 1 µg of peptide/mg NP was released from the unmodified NPs (Figure 14),
demonstrating inadequate, non-inhibitory levels of release. In comparison, CafA-modified NPs
released 23% of BAR during the first hour, and inhibitory concentrations (3.1, 2.7, 2.9, and
3.3 µg/mg) of BAR peptide after 2, 4, 8, and 24 hr. Cumulatively, after 24 hr, BAR peptide
(15.5 µg/mg) was completely released from CafA-modified BAR NPs, whereas 61% of the
encapsulated BAR (10.3 µg/mg) was released from unmodified BAR-encapsulated NPs.
Thus, after 24 hr, the total quantity of BAR released from CafA-modified NPs was significantly
higher than the amount of BAR released from unmodified NPs.
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**Table 3: Encapsulation efficiency of CafA-modified and unmodified NPs.

NP Type

BAR input
(µg/mg)

BAR output
(µg/mg)

Encapsulation
Efficiency (%)

Unmodified NPs

43

16.95 ± 0.8

39.4

CafA-modified NPs

43

15.73 ± 1.9

36.5

**Figure 14: Release kinetics of BAR peptide from unmodified and CafA-modified NPs

Cumulative release of BAR as (A) function of mass (µg BAR per mg NP) and (B) percent of
total BAR loaded over 24 hr. Asterisks denote a statistically significant difference between two
groups (* p < 0.01, ** p < 0.001, *** p < 0.0001, **** p < 0.00001).
**These data were collected together with Mohamed Y. Mahmoud

56

Determination of functionality of surface modification
Duration of retention of CafA-modified C6 NPs
CafA-modified C6 NPs were incubated with immobilized S. gordonii cells for 1 hr, after which
unbound NPs were washed and cell-associated fluorescence was measured to determine the
amount of NPs that initially bound to S. gordonii (t = 0). As shown in Figure 15A, after the first
hour of binding (t = 0), CafA-modified NPs bound to S. gordonii at a 2.3-fold higher
concentration (5.7 µg/mL), relative to non-specific avidin-modified NPs (2.5 µg/mL). The most
significant dissociation of CafA-modified NPs from S. gordonii was observed within 1 hr of
assessing initial binding (t = 1), after which NP dissociation stabilized for both CafA-modified
and avidin-modified NPs. After 8 hr, 65% (3.7 µg/mL) of CafA-modified and 56% of avidinmodified NPs (1.4 µg/mL) remained associated with S. gordonii, resulting in a 2.5-fold higher
concentration of CafA-modified NPs bound to S. gordonii (Figure 15B). These results indicate
that the ratio of CafA-modified to avidin-modified NPs bound to S. gordonii was maintained
after the first wash and suggest that CafA modification enhances NP retention by increasing
the concentration of NPs that initially bind to S. gordonii. After 8 hr, similar rates of subsequent
dissociation resulted in a higher concentration of CafA-modified NPs remaining bound to S.
gordonii.
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**Figure 15: Duration of retention of CafA-modified C6 NPs. (A) After one hour of initial
binding (t=0), a 2.3-fold higher concentration of CafA-modified C6 NPs (5.7 ug/mL) bound to
S. g. relative to avidin-modified C6 NPs (2.5 µg/mL) and this difference in concentration was
maintained for up to 8 hr. (B) 65% of CafA-modified C6 NPs remain bound to S. g. after 8 hr.
(C) Concentration of CafA-modified NPs bound to S. g. normalized against Avidin-modified
NPs. Asterisks denote a statistically significant difference between two groups (* p < 0.01, **
p < 0.001, *** p < 0.0001, **** p < 0.00001).
**Data collected together with Mohamed Y. Mahmoud
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Specificity of adhesion of CafA-modified C6 NPs
While the overall binding of CafA-modified NPs to S. gordonii is important, we sought to
assess the differences in CafA-modified NP binding across several bacteria to determine the
specificity of NP adhesion. The adherence of CafA-modified NPs to S. gordonii DL-1 was
measured relative to S. oralis SO34, S. mutans KPSP2, P. gingivalis ATCC 33277 and A.
actinomycetemcomitans 652 cells. For commensal oral streptococci, S. gordonii DL-1 and S.
oralis SO34, that express the receptor polysaccharides (RPS), there was no statistical
significance in the concentration of bound CafA-modified NPs between groups. For bacterial
groups that were RPS-negative, CafA-modified NPs bound to S. gordonii DL-1 at a 1.8-fold
higher concentration relative to S. mutans KPSP2 and 2.6-fold higher concentration relative
to P. gingivalis ATCC 33277 and A. actinomycetemcomitans 652. The concentration of CafAmodified NPs bound to S. gordonii DL-1 relative to S. mutans KPSP2, P. gingivalis ATCC
33277 and A. actinomycetemcomitans 652 was found to be statistically significant (P ≤ 0.05).
Among non-commensal streptococci, the concentration of CafA-modified NPs bound to S.
mutans KPSP2 relative to P. gingivalis ATCC 33277 and A. actinomycetemcomitans 652 was
found to be statistically significant (P ≤ 0.05).
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Figure 16: Specificity of CafA-modified C6 NP adhesion. CafA binds the receptor
polysaccharides (RPS) found only on commensal oral streptococci such as S. gordonii and
S. oralis. It does not bind to bacteria lacking the receptor and therefore, CafA-modified NPs
bound to S. gordonii DL-1 (S. g.) and S. oralis SO34 (S. o.) at a higher concentration than S.
mutans KPSP2 (S. m.), P. gingivalis ATCC 33277(P. g.), and A.actinomycetemcomitans 652
(A. a.), demonstrating specificity of adherence. Asterisks denote a statistically significant
difference between two groups (* p < 0.01, ** p < 0.001, *** p < 0.0001, **** p < 0.00001).
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CafA-modified NP-mediated Inhibition of P. gingivalis adherence to streptococci
Functional inhibition assays were performed to determine the impact of CafA-modified BAR
NPs on the inhibition of P. gingivalis adhesion to S. gordonii. Immobilized S. gordonii were
incubated with CafA-modified BAR NPs (treatment group) or CafA-modified blank NPs
(control control) for 1 hr. After the first hour of binding (t = 0) and at each subsequent time
point (t = 2, 4, 8, 12 hr) the supernatant containing the unbound NPs and released BAR was
removed and P. gingivalis was added to the control and treatment plates The plates were
incubated for 24 hr and the formed biofilms were visualized using confocal microscopy.
Representative images of treatment and control biofilms are shown in Figure 17. At each time
point (t = 0, 2, 4, 8 and 12 hr), P. gingivalis adherence to S. gordonii was significantly reduced
in the presence of CafA-modified BAR NPs, relative to control CafA-modified blank NPs
(Table 4). After initial administration for one hour (t = 0), P. gingivalis adherence was inhibited
by 87.9 ± 4.1% and maintained more than 80% inhibition after 2 and 4 hr, relative to control
CafA-modified blank NPs. After 8 and 12 hr, time frames relevant to oral administration
regimens, P. gingivalis binding to S. gordonii was inhibited by 66.3 ± 4.1% and 40.6 ± 9.3%,
demonstrating the potential of CafA-modified BAR NPs to significantly inhibit P. gingivalis
adherence to S. gordonii.
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Figure 17(A-E): Functional inhibition assay demonstrating inhibition of P. gingivalis
adherence to S. gordonii. CafA-modified BAR NPs inhibited P. gingivalis adherence for more
than 8 hr relative to CafA-modified blank NPs (control). Biofilms were visualized using confocal
microscopy and the ratio of green (P. g) to red (S. g.) fluorescence in z-stack images was
determined using Volocity software.
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Table 4: Percent inhibition of P. gingivalis adherence to S. gordonii at various time points.

Time Point
t = 0 hr
t = 2 hr
t = 4 hr
t = 8 hr
t = 12 hr

Inhibition of P.g. Adherence (%)
87.9 ± 4.1
85.5 ± 2.6
81.4 ± 9.7
66.3 ± 4.1
40.6 ± 9.3
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CHAPTER 5
DISCUSSION

The adherence of P. gingivalis to S. gordonii is a crucial, initial event which facilitates the
colonization of P. gingivalis in the oral cavity. The binding of P. gingivalis to S. gordonii is
driven by a protein−protein interaction between Mfa1, the structural subunit of the minor
fimbriae of P. gingivalis, and discrete domains of the streptococcal cell surface protein, SspB,
of the antigen I/II family [125, 127, 142, 143]. These early interactions provide ideal targets for
therapeutic interventions to limit the supragingival colonization of P. gingivalis in the oral
cavity. Previous studies have shown that a synthetic peptide designated BAR potently inhibits
P. gingivalis/S. gordonii adherence and reduces the virulence of P. gingivalis in a murine
model of periodontitis [67, 128, 129]. However, owing to the constant flow of saliva in the oral
cavity, free peptide is only transiently retained. Moreover, a higher concentration of free
peptide is needed to disrupt pre-established P. gingivalis biofilms.

To overcome this challenge, we developed polymeric nanoparticles that encapsulate BAR.
BAR-encapsulated NPs (IC50 = 0.7 µM) were found to be more efficacious relative to free
peptide (IC50 = 1.3 µM) and inhibited pre-established biofilms potently. However, similar to
free peptide, BAR-encapsulated NPs also lack a mechanism by which to prolong retention in
the oral cavity. Since BAR-encapsulated NPs release BAR peptide over the course of hours,
they may benefit from a strategy to augment their retention in the oral cavity [133]. Given this,
the goal of this study was to formulate NPs with improved binding to the GalNAcβ1-3Gal motif
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of the receptor polysaccharides (RPS) expressed by commensal oral streptococci. In parallel
we sought to prolong the release of inhibitory concentrations of BAR peptide for 8 to 12 hr, for
future application in oral hygiene products, such as oral gels, that are traditionally
administered twice daily.
CafA is the tip fimbrillin of type 2 fimbriae of A. oris, and during plaque development, it
mediates the coaggregation of A. oris with commensal oral streptococci. CafA binds to the
GalNAcβ1-3Gal motif of the RPS found on commensal oral streptococci such as S. gordonii
and S. oralis that promote P. gingivalis adherence. We hypothesized that functionalization of
BAR-encapsulated NPs with CafA would promote the adherence of BAR-encapsulated NPs
to oral commensal streptococci such as S. gordonii, indicating future potential in targeting to
S. gordonii harboring niches of the oral cavity. Since the S. gordonii/P. gingivalis interaction
promotes supragingival P. gingivalis colonization, accumulation of BAR-encapsulated NPs
and the localized, prolonged release of BAR from this niche may potently inhibit S. gordonii/P.
gingivalis biofilm formation and reduce P. gingivalis colonization of the oral cavity.
Surface modification of the NPs with ligands such as CafA can be accomplished in two ways;
(i) by chemical conjugation or physical adsorption of the ligands on the NP surface after NP
formation, or (ii) by linking the ligands to components of the NP (eg: polymer) before formation
[144]. Previous studies have shown that the lack of functional groups on the aliphatic polyester
backbone of PLGA makes coupling ligands on the surfaces of the nanoparticles particularly
challenging. While adsorption of ligands on the surfaces of the NPs is an effective approach
for surface modification, there are drawbacks associated with this approach including limited
density of surface ligands and decreased targeting effects over time due to desorption of
ligands and NP degradation [137]. It has been previously shown that coupling ligands with a
lipid (eg: palmitic acid) to form an amphiphilic molecule prior to NP synthesis enhances the
density of ligands incorporated into the PLGA matrix and helps to achvieve a stable protein
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coat on NP surfaces [137, 145, 146]. To facilitate a sustained presentation of ligands, we
conjugated CafA to palmitic acid prior to its addition during NP synthesis.
Following synthesis, we selected NPs with an intermediate density of surface ligands (20
µg/mg polymer) for further characterization and functional studies. Although in general, higher
ligand density increases binding avidity via multivalent interactions, several studies have
reported that NPs with intermediate ligand density exhibit higher binding relative to higher
ligand densities [116-118]. Several explanations have been offered for this effect including
steric interference; improper ligand orientation which may impede ligand function; or ligand
overcrowding, leading to competition between ligands for the same receptor [116-118].
Additionally, these reports have suggested that increasing the ligand density beyond a certain
threshold does not improve binding efficiency [147, 148]. While NPs were formulated with an
intermediate CafA concentration, due to the feasibility of using a practical amount of peptide
and the satisfactory release properties, these results demonstrate the effectiveness of the
formulated NPs in functionality and efficacy. Future studies may focus on improving the
efficacy of CafA-modified NPs by tuning ligand surface density to optimize binding efficiency
without impeding BAR release kinetics.

While both formulations exhibited high peptide loading, it is well known that polymeric NPs
that encapsulate hydrophilic agents demonstrate high burst release due to the entrapment of
the encapsulant in the form of small clusters on the surface or within the polymer matrix just
below the surface of the particles during synthesis [149]. Studies have shown that surface
modification using amphipathic molecules slows the release of the encapsulant from the
polymeric NPs [102, 137, 149-151] due to the increased hydrophobic stabilization and uniform
dispersion of the encapsulant in the polymer matrix [152]. Our results were consistent with
these findings in that unmodified BAR NPs demonstrated more rapid release corresponding
to a burst (< 50% peptide) within one hour of delivery. We attribute these findings to the
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release of BAR that is adsorbed at, or just underneath the surface of the polymer matrix. After
the first hour, minimal additional peptide was released from unmodified NPs. In comparison,
CafA-modified NPs demonstrated a more gradual release of BAR peptide over 24 hr, likely
because to the increased hydrophobic stabilization and uniform dispersion of the peptide
within the matrix due to the presence of the Caf-palmitate conjugates on the NP surface.
Cumulatively over 24 hr, while 61% of the BAR peptide was released from unmodified NPs,
Caf-modified NPs exhibited a near complete release of the BAR peptide. This improved
release was likely due to surface modification with hydrophilic ligands, which facilitated the
drawing out of a higher amount of BAR peptide from CafA-modified NPs, promoting a
complete release of the peptide payload.

In addition to high loading and favorable release kinetics, another desirable characteristic is
NP retention at target sites for a prolonged duration. Given the site-specific nature of
periodontal disease, local application of therapeutic agents has been found to have better
patient acceptance, reduced side-effects and improved clinical outcomes. Although
therapeutic agents applied directly to periodontal pockets are effective, they too get drained
by the gingival crevicular fluid and saliva flow. Therefore, improving the binding characteristics
of delivery vehicles can increase residence time at target sites and enhance NP efficacy. Here
we targeted CafA-modified NPs to RPS-expressing bacteria such as S. gordonii, which
promote P. gingivalis colonization. Our results suggest that CafA-modified NPs demonstrate
high binding efficiency and specificity to RPS-expressing commensal bacteria relative to other
bacteria including S. mutans, P. gingivalis and A.actinomycetemcomitans. Moreover, CafAmodified NPs remained bound to S. gordonii cell surfaces for a prolonged duration (over 8 hr).
Functionally, in a dual-species biofilm, CafA-modified NPs inhibit P. gingivalis adherence to
S. gordonii potently for up to 8 hr. While these results seem promising, future experiments
will seek to develop NPs that can be retained at target sites for longer durations (12-24 hr).
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Overall our study suggests that surface modification of NPs with specific biological ligands
such as CafA can facilitate NP targeting and adherence to specific receptors on the surfaces
of S. gordonii cells for a prolonged duration. Moreover, CafA-modified NPs release inhibitory
concentrations of the BAR peptide and potently inhibit P. gingivalis adherence to S. gordonii
for a duration of time relevant to delivery in the oral cavity. CafA-modified NPs represent an
efficacious vehicle for targeting BAR peptide to P. gingivalis preferred niches.

Future experiments will focus on optimizing the surface density of CafA and evaluating the
functionality of these NPs. We anticipate that optimizing the surface density of CafA further
will also enhance the retention, drug loading and release kinetics of modified NPs for 12 to 24
hr. In the long term, we hope to apply this work to incorporate CafA-modified NPs into oral gel
formulations and test their effectiveness in clinical trials.
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